Nitrate-responsive genetically engineered probiotics locally release TNF-α nanobodies against inflammatory bowel disease

Key Points

• Engineered probiotics effectively release TNF-α nanobodies in response to nitrate, targeting inflammatory bowel disease.
• The study demonstrated a significant release of TNF-α nanobodies, achieving levels that may influence inflammatory responses.
• Assessment using genetically engineered probiotics in a controlled model highlights therapeutic interventions for disease.
• Findings suggest potential for localized treatment options, raising implications for future probiotic-based therapies.